LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
LeMaitre Vascular, Inc.NASDAQ: LMAT
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue dips below year-ago levels
Q1 FY2026 cost of revenue of $18.16M fell 1.6% year over year, behind the +0.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.
Context
- Cost of revenue amounted to 28.5% of revenue in FY2025, down 2.9 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.6% toward the trailing-twelve-month pace of +0.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 71.06M USD
- Year-over-year change
- +3.0%
- 4-year CAGR
- +7.6%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.06M | +3.0% |
| FY2024 | 2024-12-31 | 68.96M | +3.8% |
| FY2023 | 2023-12-31 | 66.44M | +17.1% |
| FY2022 | 2022-12-31 | 56.76M | +7.0% |
| FY2021 | 2021-12-31 | 53.04M | — |
Cost of Revenue vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's LTM Mar 2026 cost of revenue of $70.77M is the lowest of the 8 companies compared; the peer median is $815.11M.
- Its year-over-year change of +0.2% is the 5th highest of 8, against a peer median of +7.2%.
- Cost of revenue amounts to 27.6% of revenue for LMAT, versus a peer median of 37.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $12.51B | +0.0% | +5.9% | 33.3% | |
| LTM Jun 2026 | $6.06B | -11.0% | +7.8% | 28.8% | |
| LTM Jun 2026 | $1.2B | -11.0% | -11.5% | 46.2% | |
| LTM Sep 2026 | $815.11M | +7.2% | +7.2% | 50.6% | |
| LTM Jun 2026 | $483.98M | +12.8% | +13.9% | 32.2% | |
| LTM Mar 2026 | $169.99M | +20.8% | +15.4% | 37.1% | |
| LTM Feb 2026 | $146.03M | +12.9% | -3.6% | 46.5% | |
| LTM Mar 2026 | $70.77M | +0.2% | +7.8% | 27.6% | |
| Peer median (excluding LMAT) | $815.11M | +7.2% | +7.2% | 37.1% | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 154.42M | 161.65M | 193.48M | 219.86M | 249.6M |
| Cost of Revenue | 53.04M | 56.76M | 66.44M | 68.96M | 71.06M |
| Gross Profit | 101.38M | 104.9M | 127.05M | 150.9M | 178.54M |
| Gross Margin | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| Research & Development | 11.8M | 13.29M | 16.97M | 15.65M | 14.14M |
| Selling, General & Admin | 53.16M | 61.67M | 72.89M | 83M | 96.49M |
| Operating Expenses | 64.96M | 78.07M | 90.34M | 98.65M | 110.63M |
| Depreciation & Amortization | 9.48M | 9.43M | 9.52M | 9.67M | 10.42M |
| EBITDA | 45.98M | 36.92M | 48.99M | 66.75M | 90.79M |
| EBITDA Margin | 29.8% | 22.8% | 25.3% | 30.4% | 36.4% |
| Operating Income | 36.43M | 26.83M | 36.71M | 52.26M | 67.91M |
| Operating Margin | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% |
| Interest Income | 197K | 986K | 3.08M | 4.95M | 13.09M |
| Interest Expense | 2.22M | 0 | 0 | 205K | 5.18M |
| Other Income / Expenses | (2.14M) | 661K | 2.76M | 4.62M | 7.27M |
| Income Before Tax | 34.29M | 27.49M | 39.48M | 56.88M | 75.18M |
| Pre-Tax Margin | 22.2% | 17.0% | 20.4% | 25.9% | 30.1% |
| Income Tax Expense | 7.38M | 6.85M | 9.37M | 12.84M | 17.45M |
| Net Income | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Net Margin | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
| EPS (Basic) | 1.27 | 0.94 | 1.36 | 1.96 | 2.55 |
| EPS (Diluted) | 1.25 | 0.93 | 1.34 | 1.93 | 2.52 |
| Weighted Avg Shares | 21.16M | 21.98M | 22.22M | 22.45M | 22.64M |
| Weighted Avg Shares (Diluted) | 21.48M | 22.17M | 22.42M | 22.78M | 22.93M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.